NL-OMON21840
Not yet recruiting
Not Applicable
Intergroup trial for children or adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab efficacy and safety in high risk patients.
Institut Gustave Roussy114, rue Edouard Vaillant94 805 - Villejuif France0 sites640 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- childhood B-cell lymphoma childhood PMLBLB-cel non-Hodgkin lymfoom (B-NHL) bij kinderenB-cel acute lymfatische leukemie (B-ALL) bij kinderen
- Sponsor
- Institut Gustave Roussy114, rue Edouard Vaillant94 805 - Villejuif France
- Enrollment
- 640
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children and adolescents aged until 18 years with untreated advanced stage B\-cell NHL or B\-AL.
Exclusion Criteria
- •HISTOLOGY AND STAGING DISEASE:
- •1\. Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With AsthmaAsthmaNCT00441441GlaxoSmithKline351
Withdrawn
Phase 2
Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual ImprovementBardet-Biedl SyndromeVisual ImpairmentNCT03490019University Hospital Tuebingen
Completed
Phase 2
A Multi-Center Phase II Study in Children and Adolescence with T-AJPRN-jRCTs041180145Watanebe Arata364
Completed
Phase 2
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab EvaluationPrimary Mediastinal Large B Cell LymphomaNCT01516567Gustave Roussy, Cancer Campus, Grand Paris47
Active, not recruiting
Phase 1
A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma.Hepatoblastoma and liver cancer (hepatocarcinoma)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2023-000036-30-PLMedical University of Gdansk60